LINTONPHARM
27.5.2022 15:02:13 CEST | Business Wire | Press release
LintonPharm Co., Ltd., a China-based biopharmaceutical company focusing on the development of T cell engaging bispecific antibodies for cancer immunotherapy, announces that preliminary results of Catumaxomab for advanced Gastric Cancer (GC) with peritoneal metastasis is published online at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
Abstract Number：
e16102
Abstract Title：
Global multi-center phase I trial of the intraperitoneal infusion of anti-EpCAM x anti-CD3 bispecific antibody catumaxomab for advanced gastric carcinoma with peritoneal metastasis.
The abstract is about the cohort A, stage I of the ongoing global phase Ⅲ trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis (clinicaltrials.gov: NCT04222114). Worldwide, GC is one of the most common cancers, contributing to more than 1 million cases per year and 5.6% of all cancer diagnoses [1] . Approximately 50% of the advanced GC patients will develop peritoneal metastasis after radical resection, along with malignant ascites in most cases. Furthermore, peritoneal metastasis is associated with poor prognosis and quality of life compared with metastasis to other organs [2] . Peritoneal metastasis is treated with systemic therapies. The estimated survival period for the patients who fail to respond to third-line therapy is limited to only 2.3-2.4 months according to multiple RCTs.
In our study, 9 GC patients with peritoneal metastasis (33% had failed third-line therapy) were treated with Catumaxomab, the median overall survival was 3.4 months, with remarkable ascites regression. Catumaxomab as an T cell engaging immunotherapy has showed promising early efficacy signals.
About Catumaxomab
Catumaxomab was approved by the European Medicines Agency in 2009 for the treatment of malignant ascites. It is a bispecific antibody that binds to EpCAM (the epithelial cell adhesion molecule) on the tumor cell--and CD3 on the T cell, recruits immune accessory cells through FcγR binding at the same time. Catumaxomab kills tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects which has been verified in animal models. Currently, Catumaxomab is being evaluated in clinical trials for both advanced gastric cancer (NCT04222114) and non-muscle invasive bladder cancer (NCT04799847).
About LintonPharm
LintonPharm Co., Ltd. is a clinical-stage, research-oriented biopharmaceutical company committed to developing innovative T cell engaging bispecific antibodies with the goal of turning malignant cancers into manageable and possibly curable diseases. LintonPharm has developed multiple bispecific antibody platforms with a great potential of refined safety and efficacy profiles, long-lasting vaccinal effects and CMC efficiency. The current pipeline includes several treatments in development for blood cancer and solid tumors. For more information, please visit www.lintonpharm.com
Reference
1. World Health Organization (WHO). Globocan 2020. Global Cancer Observatory. Accessed January 7, 2021. https://gco.iarc.fr/
2. Jennifer L.L. & Travis E.G. Optimizing outcomes for patients with gastric cancer peritoneal carcinomatosis. World J Gastrointest Oncol 2018 October 15; 10(10): 282-289.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220527005174/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GasEntec Announces New Ownership Structure, Accelerating Next Phase of Global Growth10.9.2026 11:00:00 CEST | Press release
Independent LNG infrastructure and technology company expands investment in proprietary technology, modular solutions and global project development. GasEntec Holdings Inc., a global LNG technology and assets company, today announced a new ownership structure designed to accelerate GasEntec’s next phase of growth and expand the commercialization of its proprietary LNG technologies and solutions. A consortium led by the Groupe Mimran has acquired a majority stake in GasEntec Holdings Inc., the US holding company, supporting GasEntec’s global growth. Under the new structure, GasEntec Holdings is the parent company of GasEntec’s South Korean operating business. Prior shareholders have exited in full. GasEntec’s customer relationships, contracts, engineering organization and ongoing global operations remain unchanged. GasEntec will continue to operate independently, with its technology development, engineering and operations centered in South Korea and an expanding commercial presence acro
EUMETSAT Takes Control of MTG-I210.9.2026 09:30:00 CEST | Press release
EUMETSAT’s Mission Control Centre in Darmstadt, Germany, took over control of the newest addition to its fleet of meteorological satellites, Meteosat Third Generation Imager 2 (MTG-I2), on 9 September 2026, following the successful completion of its Launch and Early Orbit Phase (LEOP). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260909889951/en/ MTG-I2 in orbit MTG-I2 launched from Europe’s Spaceport in French Guiana on 27 August 2026 and has now reached its geostationary orbit, around 36,000 km above Earth. During LEOP, carried out for EUMETSAT by Telespazio, communications with the satellite were established, its solar arrays deployed and a series of precise manoeuvres brought it to its designated orbital position. The spacecraft has now been handed over to EUMETSAT’s flight operations teams. EUMETSAT, working with ESA and European industry, will now begin extensive calibration and validation activities to prepare the s
LUMI AI Factory Selects IQM's Staged Path to Europe's First Superconducting Quantum Computer With Logical Qubits10.9.2026 09:08:00 CEST | Press release
The upgrade path contains three stages from IQM´s Halocene product line to enable a logical qubit system. The quantum computer, as part of the LUMI AI Factory initiative, is jointly owned by the participating countries of Finland, Czechia, Norway and Poland, and jointly funded by the EuroHPC Joint Undertaking. The system will be installed at CSC – IT Center for Science in Finland and integrated into the LUMI-AI computing environment to form a hybrid HPC, AI, and quantum computing platform. The deployments are in line with IQM’s development roadmap for fault-tolerant quantum computing by 2030. IQM Quantum Computers (Nasdaq: IQMX) today announced its upgrade path for a logical-qubit-capable quantum computer. The deployment to the LUMI AI Factory, led by CSC – IT Center for Science, will support R&D efforts toward fault-tolerant quantum computing and advancements in hybrid computing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home
Cyviz and SWISS Create Flexible Collaboration Hub for Hybrid Work at Scale10.9.2026 09:00:00 CEST | Press release
Watch Video Case Cyviz AS has delivered a flexible collaboration hub for Swiss International Air Lines Ltd. (SWISS), designed to support hybrid meetings, workshops, training, town halls, and internal events at scale. The project highlights how global enterprises are investing in reliable, intuitive, and versatile collaboration environments as hybrid work becomes embedded in day-to-day operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260910985990/en/ Inside the SWISS collaboration hub at their headquarters in Zurich Located at SWISS headquarters in Zurich-Kloten, Switzerland, the new collaboration hub demonstrates how enterprise collaboration spaces are evolving from traditional meeting rooms into strategic workplace infrastructure. Delivered by Cyviz, the environment supports a wide range of hybrid formats while making advanced room technology simple for everyday users. Designed to switch seamlessly between separat
Nothing Cleans Like Oral‑BiO: The Electric Toothbrush That Cleans Deeper, Smarter and Better10.9.2026 09:00:00 CEST | Press release
Oral-B iO delivers a clinically proven deeper, smarter and better clean, with 100% more plaque removal and 6x more plaque removal along the gum line, both compared to a manual toothbrush. Oral‑B, the #1 brand most used by dentists worldwide, today spotlights its most advanced brushing technology: the Oral‑B iO range. Powered by a unique 2-in-1 cleaning technology, iO is engineered to clean deeper into every gap, brush smarter with real-time pressure guidance, and deliver results that are clinically proven to be better. The proof is everything — and nothing cleans like Oral‑B iO. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260904320713/en/ Oral-B iO10 Most people know that an electric toothbrush outperforms a manual one — but not everyone knows why, or what makes one electric brush stand apart from another. Oral‑B iO makes the difference clear: deeper, smarter, better — everywhere. Cleans Deeper: The Technology Behind the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom